03724nam a22004455i 4500001001800000003000900018005001700027007001500044008004100059020001800100024003500118050001400153072001700167072002300184072001600207245011300223250001800336264007500354300006400429336002600493337002600519338003600545347002400581505127200605520091901877650001902796650002002815650001802835650001802853650002002871650001802891700007702909700007802986710003403064773002603098776003603124776003603160776003603196856004603232978-3-031-52197-3DE-He21320251030112008.0cr nn 008mamaa240424s2024    sz |    s    |||| 0|eng d  a97830315219737 a10.1007/978-3-031-52197-32doi 4aRC321-580 7aPSAN2bicssc 7aSCI0890002bisacsh 7aPSAN2thema10aIon Channels as Targets in Drug Discoveryh[electronic resource] /cedited by Gary Stephens, Edward Stevens.  a1st ed. 2024. 1aCham :bSpringer International Publishing :bImprint: Springer,c2024.  aIX, 537 p. 88 illus., 62 illus. in color.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda0 aIon Channels as Targets in Drug Discovery: outlook and perspectives -- Conservation of ligand binding between voltage-gated sodium and T-type calcium channels -- The presynaptic α2δ protein family and their therapeutic potential -- Sodium channel in central hyperexcitability disease -- Therapeutic targeting of voltage-gated potassium channels -- The contribution of genetic sequencing information to the identification and functional characterisation of two pore domain (K2P) channels as viable therapeutic targets -- The voltage-gated potassium channel KV2.1 as a multicellular drug target -- Cystic fibrosis transmembrane conductance regulator (CFTR)-targeted therapeutics for cystic fibrosis -- Validation of TMEM16A modulation as a therapeutic approach for the treatment of cystic fibrosis – the discovery of novel TMEM16A potentiators -- Targeting acid-sensing ion channels in disease -- Transient Receptor Potential Canonical (TRPC) as a Therapeutic Drug Target -- Nicotinic receptors of the neuronal and non-neuronal cholinergic systems as therapeutic targets: Opportunities and limitations -- Purinergic P2X receptors as therapeutic targets -- Immune Cell Ion Channels as Therapeutic Targets -- Ion channel tools and therapeutics from venoms and toxins.  aThis book is built around ion channel research and, more specifically, ion channels as important therapeutic drug targets. Under the editorial leadership of Gary Stephens in academic research and Edward Stevens from industry, the aim is to bring these strands together to provide a cutting-edge translational reference on ion channel drug discovery. Exploiting our knowledge of ion channel structure and function has clear current and future potential to intervene and correct the pathophysiology associated with debilitating conditions, including cardiovascular disease, diabetes, cystic fibrosis, pain, epilepsy, and neurodegenerative disorders. Individual chapters have a disease focus, also providing a “case study story” that will also appeal to a clinical audience, while background information on a given ion channel is presented to provide a solid reference for undergraduate and postgraduate teaching. 0aNeurosciences. 0aNeurochemistry. 0aPharmacology.14aNeuroscience.24aNeurochemistry.24aPharmacology.1 aStephens, Gary.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt1 aStevens, Edward.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt2 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978303152196608iPrinted edition:z978303152198008iPrinted edition:z978303152199740uhttps://doi.org/10.1007/978-3-031-52197-3